Skip to content
Screener

Alumis Inc. ALMS Enterprise value

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$152.27B+14.9%
Amgen logo
AmgenAMGN
$252.17B+23.1%
Immunome logo
ImmunomeIMNM
$1.9B+470%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$2.38B+690%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$886.04M+7,437%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$1.82B+17.9%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+686%
P/S421.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010

FAQ

What is Alumis Inc.'s enterprise value?
Alumis Inc. (ALMS) reported enterprise value of $2.77B in Q1 2026.
How has Alumis Inc.'s enterprise value changed year-over-year?
Alumis Inc.'s enterprise value increased by 1238.0% year-over-year, from $207.32M to $2.77B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.

Ask your AI about Alumis Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude